April 19, 2022
BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Below is the company's full press release. RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to...
April 28, 2021
BioAge Labs is off to a fast start in 2021, with two drugs in its pipeline now undergoing clinical trials and a third planned to start in the near future. BioAge Labs Building momentum After a $90 million Series C funding round closed late last year, BioAge has moved quickly to start the new year....